Wednesday, June 21, 2017 10:54:17 AM
Guru Score: 40%
PRICE/SALES RATIO: [FAIL]
The prospective company should have a low Price/Sales ratio. However, NAK's P/S is not available which means an opinion cannot be rendered at the present time on this variable. This is the most important variable according to this methodology, and therefore the remainder of the analysis will be provided for informational purposes.
TOTAL DEBT/EQUITY RATIO: [PASS]
Less debt equals less risk according to this methodology. NAK's Debt/Equity of 0.00% is exceptional, thus passing the test.
PRICE/RESEARCH RATIO: [PASS]
This methodology considers companies in the Technology and Medical sectors to be attractive if they have low Price/Research ratios. NAK is neither a Technology nor Medical company. Therefore the Price/Research ratio is not available and, hence, not much emphasis should be placed on this particular variable.
PRELIMINARY GRADE: No Interest in NAK At this Point
Is NAK a "Super Stock"? NO
LONG-TERM EPS GROWTH RATE: [FAIL]
This methodology looks for companies that have an inflation adjusted EPS growth rate greater than 15%. NAK's inflation adjusted EPS growth rate is not available. Hence, this methodology cannot analyze this criterion at the present time.
FREE CASH PER SHARE: [FAIL]
This methodology looks for companies that have a positive free cash per share. Companies should have enough free cash available to sustain three years of losses. This is based on the premise that companies without cash will soon be out of business. NAK's free cash per share of -0.07 fails this criterion.
THREE YEAR AVERAGE NET PROFIT MARGIN: [FAIL]
This methodology looks for companies that have an average net profit margin of 5% or greater over a three year period. NAK's three year net profit margin, which averages 0.00%, does not pass this criterion.
Everything I say,is only my opinion. DO not rely on anything I post,as buy or sell advice. DO your own homework.
Recent NAK News
- Form SC 13D - General Statement of Acquisition of Beneficial Ownership • Edgar (US Regulatory) • 11/04/2024 05:28:18 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/19/2024 10:57:25 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/15/2024 05:35:58 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/23/2024 07:33:48 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 03:26:58 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 12/29/2023 08:52:47 PM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM